Teleflex expands its hemostatic product portfolio via Z-Medica acquisition, for $500M upfront

Oct. 28, 2020 5:30 PM ETTeleflex Incorporated (TFX)TFXBy: Vandana Singh, SA News Editor1 Comment
  • Teleflex (NYSE:TFX) has agreed to acquire privately held Z-Medica, a manufacturer of hemostatic products, for an upfront cash payment of $500M, and up to an additional $25M in milestone payments.
  • Teleflex acquired certain tax attributes, valued at ~$40M, in the transaction that are expected to result in future tax benefits.
  • Liam Kelly, Chairman, President and CEO, said, “the acquisition of Z-Medica enables Teleflex to leverage strength in the hospital, EMS, and military call points, with differentiated products that complement the EZ-IO and EZPLAZ 1 product portfolio.”
  • The transaction is expected to contribute between $60M-$70M of revenue and between $0.07-$0.15 in adjusted EPS in fiscal year 2021.Beyond 2021, the company expects the acquisition to deliver a high-single digit revenue growth profile and further accretion to adjusted earnings per share.
  • The company intends to discuss this acquisition in more detail on its upcoming third-quarter 2020 earnings conference call scheduled to be held on Thursday, October 29, 2020 at 8:00 am ET.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.